Brief: Bolt Biotherapeutics Announces Positive Topline Data From Bdc-1001 Phase 1 Dose-Escalation Trial
29/03/2023 22:03
March 29 (Reuters) - Bolt Biotherapeutics Inc BOLT.O :
* BOLT BIOTHERAPEUTICS ANNOUNCES POSITIVE TOPLINE DATA FROM
BDC-1001 PHASE 1 DOSE-ESCALATION TRIAL IN HER2-EXPRESSING
TUMORS, SUPPORTING ADVANCEMENT TO PHASE 2 CLINICAL STUDIES
Source text for Eikon: ID:nGNX89v4tz
Further company coverage: BOLT.O
((Reuters.Briefs@thomsonreuters.com;))